N-[4-(6-(2-benzyloxyphenyl)pyrimidin-4-ylamino)benzyl]methanesulfonamide | 1313219-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-[4-(6-(2-benzyloxyphenyl)pyrimidin-4-ylamino)benzyl]methanesulfonamide
• 英文别名: N-[[4-[[6-(2-phenylmethoxyphenyl)pyrimidin-4-yl]amino]phenyl]methyl]methanesulfonamide
• CAS: 1313219-58-7
• 化学式: C₂₅H₂₄N₄O₃S
• 分子量: 460.557
• InChiKey: LQXCCFMKCUBQFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  102
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY<br/>[FR] DÉRIVÉS DE 4-PHÉNYLAMINO-PYRIMIDINE AYANT UNE ACTIVITÉ D'INHIBITION D'UNE PROTÉINE KINASE
  申请人：VICHEM CHEMIE KUTATO KFT

  公开号：WO2011077171A1

  公开（公告）日：2011-06-30

  The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula -NH-SO2-R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

  该发明涉及一般式（I）的化合物及其药用可接受的盐和溶剂化合物，其中R1为卤素、乙烯基芳基、取代芳基、杂芳基或苯并[1,3]二噁唑基团，W为式-NH-SO2-R2或杂芳基或NHR3基团，其中R3为氢或杂芳基；n为1、2、3或4。此外，本发明涉及一种含有至少一种一般式（I）的化合物和/或其药用可接受的盐或溶剂化合物的药物组合物，并用于制备用于预防和/或治疗蛋白激酶相关疾病，特别是CDK9相关疾病，如细胞增殖性疾病、传染病、疼痛、心血管疾病和炎症的药物组合物。
• 4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY
  申请人：Greff Zoltán

  公开号：US20120258968A1

  公开（公告）日：2012-10-11

  The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R 1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula —NH—SO 2 —R 2 or heteroaryl group or NHR 3 group where R 3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

  本发明涉及通式（I）的化合物及其药用盐和溶剂化物，其中R1为卤素，乙烯基芳基，取代芳基，杂芳基或苯并[1,3]二噁唑基团，W为式—NH—SO2—R2或杂芳基或NHR3基团，其中R3为氢或杂芳基；n为1、2、3或4。此外，本发明还涉及含有至少一种通式（I）的化合物和/或其药用盐或溶剂化物的药物组合物，以及将它们用于制备用于预防和/或治疗蛋白激酶相关疾病，特别是CDK9相关疾病（例如细胞增殖性疾病、传染病、疼痛、心血管疾病和炎症）的药物组合物。
• US9040529B2
  申请人：——

  公开号：US9040529B2

  公开（公告）日：2015-05-26